Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients aged ≥18 years
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and Life expectancy of at least 12 weeks
Patients are able and willing to provide bone marrow biopsies/aspirates as requested by the protocol
Patients with confirmed advanced hematological malignancies
Negative serum pregnancy test
Women and men of reproductive potential must agree to use highly effective contraception when sexually active.
Ability to understand and the willingness to sign a written informed consent.
Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤1.5 times ULN)
Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN
You may not be if
Presence of active/uncontrolled central nervous system involvement
History of clinically significant cardiac disease; uncontrolled hypertension
Left ventricular ejection fraction (LVEF) \< 45%
Allogeneic stem cell transplant within 100 days before first dose of study drug
Known history of human immunodeficiency virus (HIV) infection
Chronic or active hepatitis B or C, requiring antiviral therapy
Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study
Serious, uncontrolled infection
Unresolved chronic toxicity \> grade 1 from prior therapy
Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study
Clareo Health | Phase I Trial of BAY1251152 for Advanced Blood Cancers
